mucosolvan沐舒坦品牌怎么样 申请店铺

我要投票 mucosolvan沐舒坦在医疗器械行业中的票数:881 更新时间:2026-02-14
mucosolvan沐舒坦是哪个国家的品牌?「mucosolvan沐舒坦」是 上海勃林格殷格翰药业有限公司 旗下著名品牌。该品牌发源于德国,在1885年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力mucosolvan沐舒坦品牌出海!将品牌入驻外推网,定制mucosolvan沐舒坦品牌推广信息,可以显著提高mucosolvan沐舒坦产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

mucosolvan沐舒坦怎么样

咳嗽药十大品牌,1885年创于德国,以生产酒石酸,乳酸等化工产品起家,致力于研发、生产和营销药品的创新企业


勃林格殷格翰是上较大、成功的私人拥有的制药集团。自1885年成立至今,家族拥有的勃林格殷格翰一直专注于研发、生产和营销创新的药品。主要业务包括处方药,消费自主保健药品,生物制药及动物保健。经过百年的发展,勃林格殷格翰的足迹从德国莱茵河畔延伸向全球40多个国家和地区。

在全球

1885年,阿尔伯特.勃林格先生在德国法兰克福附近的殷格翰城创立了勃林格殷格翰公司。

一百多年来,研究与开发驱动着公司的发展。从最初生产酒石酸,乳酸等化工产品开始,到今天许多广为人知药品的推出,勃林格殷格翰公司在研发上的巨额投入使其在呼吸、心血管、中枢神经、肠胃道等领域拥有优秀的产品,从而赢得有利的市场地位。至今公司已在德国、意大利、奥地利、美国、加拿大、阿根廷和日本设立7个研发中心并投入巨资用于新产品的研究与开发。

在中国

1994年3月勃林格殷格翰以办事处的形式进入中国,揭开了在中国的发展篇章。1995年5月,勃林格殷格翰国际贸易(上海)有限公司注册成立。1998年初进驻上海张江“药谷”成立上海勃林格殷格翰药业有限公司,投资额达2900万美元,标志着勃林格扎根中国的决心。位于张江的现代化工厂,引进了专业的制药设备,设计和管理标准可以和任何其它国家的勃林格殷格翰工厂媲美。工厂严格按照国际GMP标准生产。

勃林格殷格翰在中国的主要业务包括处方药,消费者自主保健药品及动物保健。业务范围遍及全国各主要省市和地区。公司不断把其优秀的产品带来中国市场,上市的产品覆盖呼吸、心血管、中枢神经、抗爱滋病等重要领域,并在业界和市场获得了广泛的美誉和认可。

保健业务

随着人们自我保健意识的提高, 用于维持和改善健康、预防疾病,及治疗一些轻微疾病如感冒咳嗽等的消费者自主保健药品正越来越显示其重要性。勃林格殷格翰自主保健药品部专注于非处方药和保健食品的研制生产和销售。旗下产品线主要涵盖身心健康,感冒咳嗽,解热镇痛及血管保健等四个品类。

作为勃林格殷格翰公司的核心业务之一,专注于为中国的消费者提供高品质的自主保健药品。沐舒坦® 片剂和口服溶液均已进入非处方药目录。它能有效调节气道的浆液和粘液分泌,活化纤毛粘液运输系统,能发挥表面活性物质的正常保护功能,因而廓清效果深入肺泡。沐舒坦疗效显著,深受广大患者欢迎,而口服溶液更因可口的水果口味得到儿童和家长的喜欢。


The top ten brands of cough medicine, founded in 1885 in Germany, started with the production of tartaric acid, lactic acid and other chemical products, and the innovative enterprise, bringer Ingelheim, devoted to the research, development, production and marketing of drugs, is a large and successful privately owned pharmaceutical group. Since its establishment in 1885, the family owned Boehringer Ingelheim has been focusing on the research and development, production and marketing of innovative drugs. Its main businesses include prescription drugs, consumer self health care drugs, biopharmaceuticals and animal health care. After a hundred years of development, Boehringer Ingelheim's footprint extends from the Rhine River in Germany to more than 40 countries and regions around the world. In 1885, Albert bringer founded the company in the city of Ingelheim near Frankfurt, Germany. For more than 100 years, research and development has driven the development of the company. From the initial production of tartaric acid, lactic acid and other chemical products to the launch of many well-known drugs today, the company's huge investment in research and development makes it have excellent products in the fields of respiration, cardiovascular, central nervous system, gastrointestinal tract and other fields, so as to win a profitable market position. So far, the company has set up 7 R & D centers in Germany, Italy, Austria, the United States, Canada, Argentina and Japan and invested heavily in the research and development of new products. In March 1994, Brigitte Ingelheim entered China in the form of an office, opening a chapter of development in China. In May 1995, bringer Ingelheim international trade (Shanghai) Co., Ltd. was registered and established. At the beginning of 1998, Shanghai bolingeringelheim Pharmaceutical Co., Ltd. was established in Zhangjiang "pharmaceutical Valley" in Shanghai, with an investment of 29 million US dollars, marking Bolinger's determination to take root in China. The modern chemical plant in Zhangjiang has introduced professional pharmaceutical equipment, and its design and management standards are comparable to those of any other breingelheim plant. The factory strictly follows the international GMP standard production. The main business of Boehringer Ingelheim in China includes prescription drugs, consumer independent health care drugs and animal health care. The business scope covers all major provinces, cities and regions of the country. The company continues to bring its excellent products to the Chinese market. The products on the market cover breathing, cardiovascular, central nervous system, anti AIDS and other important fields, and have gained a wide reputation and recognition in the industry and market. With the improvement of people's self-awareness of health care, the importance of consumer independent health care drugs used to maintain and improve health, prevent diseases, and treat some minor diseases such as cold and cough is becoming more and more obvious. Boehringer Ingelheim's independent health medicine department focuses on the development, production and sales of over-the-counter drugs and health food. Its product line mainly covers four categories: physical and mental health, cold and cough, antipyretic and analgesic, and vascular health care. As one of the core businesses of Boehringer Ingelheim, it focuses on providing high-quality independent health care drugs for Chinese consumers. Both ambroxol ® tablets and oral solutions have entered the OTC list. It can effectively regulate the secretion of serous and mucus in the airway, activate the ciliated mucus transport system, and play the normal protective function of surfactant, so the clearance effect goes deep into the alveoli. Ambroxol is very effective and popular among patients, while oral solution is popular among children and parents for its delicious fruit taste.

本文链接: https://brand.waitui.com/e15ab3121.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

奥联电子:控股股东终止控制权转让

36氪获悉,奥联电子公告,公司收到控股股东瑞盈资产出具的《通知函》,受让方潮成创新未按约定足额支付第一期股份转让对价,已构成违约。据此,瑞盈资产向潮成创新发出《解除通知函》,自潮成创新收到函件起,双方签署的《股份转让协议》解除。本次股份转让协议解除后,本次控制权转让事项相应终止,公司控股股东仍为瑞盈资产,实际控制人仍为钱明飞。

2小时前

润泽科技:拟购买广东润惠42.56%股权,股票将于2月24日复牌

36氪获悉,润泽科技公告,公司拟向中金算力基金等12名投资者通过发行可转换公司债券的方式购买其合计持有的广东润惠科技发展有限公司42.56%股权,并向不超过35名特定投资者发行股份募集配套资金,截至本预案摘要签署日,标的公司的审计和评估工作尚未完成,本次交易的具体交易价格尚未确定。公司股票将于2026年2月24日开市起复牌。广东润惠的主营业务与上市公司相同,主要为IDC业务和AIDC业务。

2小时前

美股大型科技股盘前普跌,英特尔跌超1%

36氪获悉,美股大型科技股盘前普跌,截至发稿,英特尔跌超1%,特斯拉跌0.82%,亚马逊跌0.73%,Meta跌0.49%,谷歌跌0.44%,苹果跌0.14%,微软跌0.03%,英伟达涨0.03%。

2小时前

商务部新闻发言人就荷公布安世半导体案裁决结果答记者问

36氪获悉,商务部新闻发言人就荷公布安世半导体案裁决结果答记者问。有记者问:2月11日,荷兰企业法庭公布安世半导体案裁决结果,决定对安世半导体涉嫌管理不善开展调查。请问中方对此有何评论?答:中方注意到相关消息。我们认为,当务之急是要恢复全球半导体供应链稳定畅通,这是包括中荷在内的国际业界的共同利益诉求。希望荷方相向而行,从维护全球半导体产业链供应链稳定的大局出发,为双方企业协商建设性解决内部纠纷创造有利条件。

2小时前

热门中概股美股盘前多数下跌,理想汽车跌超2%

36氪获悉,热门中概股美股盘前多数下跌,截至发稿,理想汽车跌超2%,京东跌超1%,小鹏汽车跌0.79%,阿里巴巴跌0.72%,百度跌0.57%,爱奇艺跌0.55%,拼多多涨0.59%,哔哩哔哩涨0.26%。

2小时前

本页详细列出关于mucosolvan沐舒坦的品牌信息,含品牌所属公司介绍,mucosolvan沐舒坦所处行业的品牌地位及优势。
咨询